Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Simple blood test may spot lung cancer earlier

NCT ID NCT07465848

Diagnosis Sponsor: Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether measuring telomeres (parts of your DNA) in a blood sample can help doctors diagnose lung cancer. Researchers will collect blood from 1,200 people, including those with lung cancer and healthy volunteers, to build a predictive algorithm. The goal is to create a simple, non-invasive tool that could flag lung cancer risk and assist in early diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood sample collection for telomere biomarker analysis
What this could lead to
If successful, this could lead to a simple blood test that helps doctors diagnose lung cancer earlier and more accurately.
What could go wrong
This is an early-stage diagnostic study, not a treatment trial. The test may not prove accurate enough for widespread use, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Case Group: * Person aged 45 years or older at the time of signing the consent form. * Person with a current anatomopathologically confirmed diagnosis of small-cell or non-small cell lung cancer. * Not having received any oncological treatment prior to sample collection (surgery, radiotherapy, or systemic treatment with chemotherapy or immunotherapy). Control Group: Cohort A (High risk controls): * Person aged 45 years or older at the time of signing the consent form. * High risk of lung cancer, defined as having a smoking history of at least 20 pack-year and currently smoking or having quit within the past 15 years. * No diagnosis or suspicion of lung cancer. Asymptomatic individuals who have undergone a chest computed tomography (CT) scan for lung cancer screening within the 12 months prior to signing the informed consent and as part of routine clinical practice, with a LUNG-RADS score of 3 or lower, will be included. Cohort B (Low-risk controls): * Person aged 45 years or older at the time of signing the consent form. * Without high risk of lung cancer according to the criteria defined in cohort A. * No diagnosis or suspicion of lung cancer. Exclusion Criteria: * History of any malignant neoplasm, except for subjects with tumors in localized stages who have undergone radical treatment and have been disease-free for at least five years. * Patient diagnosed with lung cancer who has already started oncological treatment before sample collection. * Patient who has undergone a biopsy or any invasive procedure or minor surgery less than 48 hours ago. * Patient who has undergone major surgery less than 7 days ago. * Patient with severe chronic kidney disease, defined as a glomerular filtration rate below 15 ml/min. * Patient with severe liver disease, defined as Child-Pugh C. * Active infection, or treated less than 4 weeks ago. * Vulnerable population, for example, minors, prisoners, pregnant women, adults physically or mentally incapable of giving consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Health adult subjects are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease lung cancer lung neoplasm non-small cell lung carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Health adult subjects Lung cancer (diagnosis) Patient

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    12 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clínica Universidad de Navarra

    RECRUITING

    Madrid, Madrid, Spain

  • Complejo Hospitalario de Toledo

    RECRUITING

    Toledo, Toledo, Spain

  • HM Sanchinarro/CIOCC

    RECRUITING

    Madrid, Madrid, Spain

  • Hospital General Universitario de Elche

    RECRUITING

    Elche, Alicante, Spain

  • Hospital Universitari I Politècnic La Fe

    RECRUITING

    Valencia, Valencia, Spain

  • Hospital Universitario 12 Octubre

    RECRUITING

    Madrid, Madrid, Spain

  • Hospital Universitario Central de Asturias

    RECRUITING

    Oviedo, Principality of Asturias, Spain

  • Hospital Universitario Clínico San Carlos

    RECRUITING

    Madrid, Madrid, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    RECRUITING

    Madrid, Madrid, Spain

  • Hospital Universitario Marqués de Valdecilla

    RECRUITING

    Santander, Cantabria, Spain

  • Hospital del Mar

    RECRUITING

    Barcelona, Barcelona, Spain

  • Institut Catalá D'Oncologia Badalona (ICO)

    RECRUITING

    Barcelona, Barcelona, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.